Results 71 to 80 of about 29,580 (292)

Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib

Infection and Drug Resistance, 2020
Emiko Sakiyama, Yoshiaki Chinen, Taku Tsukamoto, Tomoko Takimoto-Shimomura, Saeko Kuwahara-Ota, Yayoi Matsumura-Kimoto, Yuji Shimura, Tsutomu Kobayashi, Shigeo Horiike, Junya Kuroda Division of Hematology and Oncology, Department of Medicine, Kyoto ...
Sakiyama E, Chinen Y, Tsukamoto T, Takimoto-Shimomura T, Kuwahara-Ota S, Matsumura-Kimoto Y, Shimura Y, Kobayashi T, Horiike S, Kuroda J   +9 more
doaj  

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

Haematologica, 2015
Ruxolitinib, a potent Janus kinase 1/2 inhibitor, resulted in rapid and durable improvements in splenomegaly and disease-related symptoms in the 2 phase III COMFORT studies.
Alessandro M. Vannucchi, Hagop M. Kantarjian, Jean-Jacques Kiladjian, Jason Gotlib, Francisco Cervantes, Ruben A. Mesa, Nicholas J. Sarlis, Wei Peng, Victor Sandor, Prashanth Gopalakrishna, Abdel Hmissi, Viktoriya Stalbovskaya, Vikas Gupta, Claire Harrison, Srdan Verstovsek   +14 more
doaj   +1 more source

Linezolid prevents fibroblast activation and ameliorates tissue fibrosis by inhibition of mitochondrial translation

Arthritis &Rheumatology, Accepted Article.
Background Beyond its role as a ribosome‐targeting antibiotic, linezolid was recently shown to modulate immune responses by inhibiting mitochondrial translation. Since mitochondrial dysfunction is implicated in various fibrotic diseases, including systemic sclerosis (SSc), this study aimed to evaluate the antifibrotic potential of linezolid and ...
Xuezhi Hong, Yanhua Xiao, Haodong Qi, Shihao Zhu, Tim Filla, Andrea‐Hermina Györfi, Yi‐Nan Li, Meilin Xu, Langxian Zhi, Thuong Trinh‐Minh, Clara Dees, Georg Schett, Jörg H.W. Distler, Alexandru‐Emil Matei   +13 more
wiley   +1 more source

Effects of Renal and Hepatic Impairment on the Pharmacokinetics of Zilurgisertib

British Journal of Clinical Pharmacology, EarlyView.
Aim Small‐molecule activin receptor‐like kinase‐2 inhibitor zilurgisertib (INCB000928) is under investigation in a pivotal trial for the treatment of fibrodysplasia ossificans progressiva (FOP), an ultrarare genetic condition. This analysis assessed effects of renal and hepatic impairment on zilurgisertib pharmacokinetics.
Yan‐ou Yang, Yunlan Fang, Phillip Wang, Xiang Liu, Jay Getsy, Kevin Rockich   +5 more
wiley   +1 more source

MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling. [PDF]

, 2015
Work in the Green lab is supported by Leukemia and Lymphoma Research, Cancer Research UK, the NIHR Cambridge Biomedical Research Centre, the Cambridge Experimental Cancer Medicine Centre, and the Leukemia and Lymphoma Society of America.
A Tefferi, A Tefferi, Claire N. Harrison, E Puigdecanet, F Passamonti, H Yoshida, J Nangalia, John T. Reilly, M Michalak, M Wictome, P Guglielmelli, R Rampal, S Schwemmers, S Verstovsek, S Verstovsek, T Klampfl   +15 more
core   +1 more source

Binding of the small-molecule kinase inhibitor ruxolitinib to membranes does not disturb membrane integrity

Biochemistry and Biophysics Reports, 2020
Ruxolitinib is a small-molecule protein kinase inhibitor, which is used as a therapeutic agent against several diseases. Due to its anti-inflammatory impact, ruxolitinib has also been considered recently for usage in the treatment of Covid-19.
Markus Fischer, Meike Luck, Maximilian Werle, Holger A. Scheidt, Peter Müller   +4 more
doaj   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies [PDF]

, 2015
Gene expression profiling has implicated several intracellular signalling cascades, including the JAK/STAT pathway, in the pathogenesis of particular subtypes of lymphoma.
Gandhi, Maher K., Scott, Linda M.
core   +1 more source

Ruxolitinib add-on therapy in steroid-refractory graft-vs-host disease following hematopoietic cell transplantation: A single institutional experience [PDF]

, 2023
Yi-Lun Wang, Tsung‐Yen Chang, Yu‐Chuan Wen, Shu-Ho Yang, Yi-Wen Hsiao, Shih‐Hsiang Chen, Tang‐Her Jaing   +6 more
openalex   +1 more source

Molecular imprinting for neurology: Materials, applications, and limitations

Ibrain, EarlyView.
Molecularly imprinted materials: diagnostic, therapeutic and research applications in neurology. Molecularly imprinted materials offer high specificity and affinity for target molecules in neurological applications. This review highlights their synthesis, characterisation, and use in diagnostics, research and therapeutics.
Xiaohan Ma, Yingqi Ma, Claudia Marino, Alessandro Poma   +3 more
wiley   +1 more source